Agent consensus
OVERWEIGHT
Multi-agent note output
MDT
Equity research — MDT (as of 2026-08-07)
Updated Aug 7, 2026
Coverage
MDT
Freshness
3 days ago
Market chart
Price context alongside the research narrative.
How the call aged
A simple read on whether this desk view matched what happened in the market over the next 5 trading days, with recent price context from the as-of date.
Desk view: OVERWEIGHTNot gradedVs peers: Middle of packAwaiting market data
Price move
—
2026-08-07 → awaiting data
5-day trend
+2.07%
20-day trend
+3.92%
Recent volatility
+29.16%
vs SPY (5d): -1.44%
Close 87.16 → —
Desk briefing
MDT is a diversified large-cap medtech franchise in the middle of a product-cycle-driven turnaround. Over a 12-month investment horizon, the structural story is favorable: new therapeutic platforms (VT ablation with CE mark, continued AF...
Full research note
Presentation-ready note with specialist analyst agents, bull and bear agent debate, trader agent synthesis, risk challenge, and portfolio sign-off.
WebserviceX.NET Research Desk
MDT Equity Research Note
Summary
MDT is a diversified large-cap medtech franchise in the middle of a product-cycle-driven turnaround. Over a 12-month investment horizon, the structural story is favorable: new therapeutic platforms (VT ablation with CE mark, continued AF...
Bias
OVERWEIGHT
Horizon
Tactical multi-week
Key risk
Event-driven repricing risk if expectations diverge from incoming evidence.
Catalyst watch
Guidance only — this is not a tactical rating or a horizon override. The 12-month structural stance is OVERWEIGHT, so the trader should treat any pullbacks as opportunities to build toward an overweight position rather than as reasons to exit.